Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.

摘要

Spontaneous rupture of the spleen is a rare but serious and life-threatening complication of treatment with granulocyte colony-stimulating factor (G-CSF). A few case reports address the occurrence of splenic rupture after filgrastim therapy, mostly in healthy donors of peripheral blood stem cells, but also in patients with acute myelogenous leukemia, myelodysplastic syndrome and amyloidosis.1"5 A recent article by Arshad et al.6 describes a case of splenic rupture in a patient with myelodysplastic syndrome following administration of pegfilgrastim. The compound has recently been approved to shorten neutropenia and decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs. We report a case of splenic rupture in a completely different clinical situation after the use of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation (PBSCT).